Axa
VTAE

Axa’s VITAE PHARMACEUTICALS INC COMMON STOCK VTAE Stock Holding History

Axa’s Portfolio VTAE Stock Details VTAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-2,376
Closed -$43K – 1498
2015
Q4 		$43K Sell
2,376
-869
-27% -$12K ﹤0.01% 1311
2015
Q3 		$36K Buy
+3,245
New +$34.5K ﹤0.01% 1375

Other funds holding VTAE

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Axa's VTAE Position: Q1 2016 in Review

Axa sold out of VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) in Q1 2016, closing a stake of 2,376 shares — an estimated $43K sold.

Axa first reported a position in VTAE in Q3 2015 and held it in 2 quarters. The position peaked at $43K in Q4 2015. 78 funds tracked by Wall St. Rank hold VTAE as of Q1 2016.

  • Axa reported no remaining VITAE PHARMACEUTICALS INC COMMON STOCK position as of Q1 2016 after selling out during the quarter.
  • Axa sold 2,376 VITAE PHARMACEUTICALS INC COMMON STOCK shares in Q1 2016, an estimated $43K.
  • Axa first reported a position in VITAE PHARMACEUTICALS INC COMMON STOCK in Q3 2015 and held it in 2 quarters.
  • Axa's VITAE PHARMACEUTICALS INC COMMON STOCK position peaked at $43K in Q4 2015.
  • 78 funds tracked by Wall St. Rank held VITAE PHARMACEUTICALS INC COMMON STOCK as of Q1 2016.

Based on Axa's 13F filing for Q1 2016, filed 13 May 2016.